Apellis’ Syfovre on the comeback trail from vasculitis worries after $74M in initial Q3 sales

Apel­lis Phar­ma­ceu­ti­cals’ eye drug Syfovre is on track for a re-ac­cel­er­at­ed launch af­ter a re­al world safe­ty scare, with the com­pa­ny an­nounc­ing pre­lim­i­nary US net sales of $74 mil­lion in the third quar­ter.

Syfovre won FDA ap­proval for ge­o­graph­ic at­ro­phy sec­ondary to wet age-re­lat­ed mac­u­lar de­gen­er­a­tion in Feb­ru­ary and launched in March. But its tra­jec­to­ry was soon be­set by un­ex­pect­ed re­al world events of in­traoc­u­lar in­flam­ma­tion and reti­nal vas­culi­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.